Tracy Zimmermann
22Patents
8h-index
18Co-inventors
68Inventor score
Filing activity: May 27, 2005 → Jun 24, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9290760B2 | Modified iRNA agents | Chemistry; Metallurgy | 90 | Active |
| US9796974B2 | Modified RNAi agents | Chemistry; Metallurgy | 85 | Active |
| US7928217B2 | Nuclease resistant double-stranded ribonucleic acid | Chemistry; Metallurgy | 36 | Active |
| US9399775B2 | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases | Chemistry; Metallurgy | 29 | Active |
| US8334373B2 | Nuclease resistant double-stranded ribonucleic acid | Chemistry; Metallurgy | 28 | Active |
| US10208307B2 | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases | Chemistry; Metallurgy | 11 | Active |
| US10570391B2 | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases | Chemistry; Metallurgy | 8 | Active |
| US10668170B2 | Modified RNAi agents | Chemistry; Metallurgy | 8 | Active |
| US8623838B2 | Organic compositions to treat HSF1-related diseases | Emerging Cross-Sectional Technologies | 5 | Active |
| US8293718B2 | Organic compositions to treat HSF1-related diseases | Emerging Cross-Sectional Technologies | 5 | Active |
| US8481509B2 | Organic compositions to treat HSF1-related diseases | Chemistry; Metallurgy | 5 | Active |
| US11286486B2 | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases | Chemistry; Metallurgy | 4 | Active |
| US11406716B2 | Modified RNAi agents | Chemistry; Metallurgy | 3 | Active |
| US8993746B2 | Nuclease resistant double-stranded ribonucleic acid | Chemistry; Metallurgy | 3 | Active |
| US10683501B2 | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases | Chemistry; Metallurgy | 3 | Active |
| US10287582B2 | Organic compositions to treat HSF1-related diseases | Emerging Cross-Sectional Technologies | 2 | Active |
| US9540643B2 | Organic compositions to treat HSF1-related diseases | Emerging Cross-Sectional Technologies | 2 | Active |
| US9096637B2 | Organic compositions to treat HSF1-related diseases | Emerging Cross-Sectional Technologies | 2 | Active |
| US12091661B2 | Organic compositions to treat HSF1-related diseases | Emerging Cross-Sectional Technologies | 0 | Active |
| US12290573B2 | Modified RNAi agents | Chemistry; Metallurgy | 0 | Active |
| US12049628B2 | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases | Chemistry; Metallurgy | 0 | Active |
| US11091761B2 | Organic compositions to treat HSF1-related diseases | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.